Hinz v. Neuroscience, Inc.

538 F.3d 979, 2008 U.S. App. LEXIS 17842, 2008 WL 3876312
CourtCourt of Appeals for the Eighth Circuit
DecidedAugust 22, 2008
Docket07-2694, 07-2699
StatusPublished
Cited by34 cases

This text of 538 F.3d 979 (Hinz v. Neuroscience, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hinz v. Neuroscience, Inc., 538 F.3d 979, 2008 U.S. App. LEXIS 17842, 2008 WL 3876312 (8th Cir. 2008).

Opinion

BENTON, Circuit Judge.

In this diversity case, Dr. Martin Hinz and Neuroresearch Clinics, Inc. (collectively “Hinz”) sued Neuroscience, Inc. and Gottfried Kellermann (collectively “Keller-mann”) for breach of contract. A jury returned a verdict for Hinz, awarding $1,989,373 in damages. The district court 2 reversed the damage award on Kel-lermann’s motion for judgment as a matter of law. The court denied Hinz’s motions for permanent injunction, pre- and post-judgment interest, and attorney’s fees and costs. Hinz appeals. Kellermann cross appeals, claiming the court erred in allowing parol evidence to interpret the con *982 tract. Having jurisdiction under 28 U.S.C. § 1291, this court affirms.

I.

Hinz developed the D5 product series, including D5, D5 Extra, and D5 Mucuna to treat neurotransmitter dysfunction. The primary ingredient in D5 Mucuna was Mu-cuna pruriens; the primary ingredients in D5 were L-Dopa (from standardized Mu-cuna pruriens) and 5-HTP.

Hinz and Kellermann reached a Joint Working Agreement on October 14, 2001. The agreement permitted Kellermann to distribute Hinz’s products in exchange for paying Hinz a royalty rate of 43 percent per product.

In August 2002, Hinz and Kellermann created Neuroscience, Inc. to develop and sell amino acid supplement products. Neuroscience distributed and marketed Hinz’s products, including D5 and D5 Mu-cuna. Neuroscience agreed to pay Hinz a royalty rate and salary, in addition to business expenses. On November 30, 2002, Kellermann terminated the joint business relationship. Kellermann stayed with Neuroscience, while Hinz started Neurore-search Clinics, Inc. Within weeks, Neuroscience contacted all the customers in its database to persuade them to stay with it. About 80 percent of the customers were contacts brought to Neuroscience by Hinz, while the remaining 20 percent were contacts Hinz and Kellermann established together. After the split, Neuroscience sold Hinz’s products, without paying him a royalty rate.

In January 2003, Kellermann sued Hinz; Hinz countersued. The dispute was settled during a court-mediated settlement conference on May 23, 2003. The settlement was memorialized in a written agreement. As relevant, the agreement, effective September 1, 2003, required Kel-lermann to:

• “permanently discontinue the promotion, sale and use of the following tradenames, trademarks and products using said tradenames and trademarks: Cysre-plete, NeuroReplete, RepleteExtra, D5, D5 Extra, D5 Mucuna, The Replete Program, and L-tyrosine in combination with 5-HTP,”
• “permanently discontinue the promotion, marketing and sale of the D5 product series,” and
• “make no further use of any trademarks and amino acid formulations specifically prohibited by this agreement for which [Hinz] had been paid royalties in the past.”

Four months later, Hinz sued Keller-mann for breach of the settlement agreement, alleging Kellermann was selling products containing the ingredients Mucu-na pruriens and Mucuna pruriens in combination with 5-HTP. Before trial, the district court ruled that the settlement agreement was ambiguous on its face. It permitted Hinz and Kellermann to introduce parol evidence to interpret the terms of the contract. The jury found a breach of contract, awarding $1,989,373 in lost-profit damages.

After trial, Kellermann moved for judgment as a matter of law, or alternatively a new trial under Rule 50(b) of the Federal Rules of Civil Procedure. The district court granted judgment as a matter of law on damages, concluding Hinz provided no reasonable basis for the calculation of damages. However, the court denied Kel-lermann’s motion for new trial, ruling it untimely. The court also denied Hinz’s motions for permanent injunction, pre- and post-judgment interest, and attorney’s fees and costs. Hinz appeals, contending the district court erred in (1) reversing the damage award because it lacked jurisdiction; (2) concluding there was insufficient evidence for the damage award; (3) in *983 structing the jury on the measure of damages; and (4) denying Hinz a permanent injunction, pre- and post-judgment interest, and attorney’s fees and costs. Keller-mann cross-appeals, objecting to the use of parol evidence.

II.

Hinz argues Kellermann failed to comply with the “particularity” requirement of Rule 7(b) of the Federal Rules of Civil Procedure in his post-verdict motion. Hinz thus concludes the district court lacked jurisdiction to enter the amended judgment reversing the damage award.

At the close of evidence, Kellermann moved for judgment as a matter of law, explaining orally the basis for the motion. See Fed.R.Civ.P. 50(a). Specifically, he disagreed with the use of parol evidence and claimed there was insufficient evidence to prove damages. Post-verdict, Keller-mann renewed his motion, stating simply: “we would like to renew our Rule 50 motion for judgment as a matter of law.” See Fed.R.Civ.P. 50(b). Exactly ten days after trial, Kellermann filed motions for judgment as a matter of law, and alternatively a new trial. See id. The post-verdict motions did not describe the grounds on which they were based. The next day, however, Kellermann filed a supporting memorandum detailing the grounds for the motions. Kellermann attacked the verdict, the use of parol evidence, and other “irrelevant and prejudicial” evidence. The district court ruled that for the issues of damages and parol evidence the motions were timely and stated with particularity. For the issue of irrelevant and prejudicial evidence, the motion was untimely.

Because the dispute involves the legal jurisdiction of the court, this court reviews de novo. See Andreas v. Volkswagen of Am., Inc., 336 F.3d 789, 793 (8th Cir.2003).

“Rule 7 is a general rule that applies to all motions.” Id. It requires a request for a court order to be made by motion, which shall (1) be in writing, unless made during a hearing or a trial, (2) state with particularity the grounds for seeking the order, and (3) state the relief sought. Fed.R.Civ.P. 7(b). The particularity requirement gives notice to the court and the opposing party, providing the opposing party “a meaningful opportunity to respond and the court with enough information to process the motion correctly.” Andreas, 336 F.3d at 793. However, the particularity requirement “should not be applied in an overly technical fashion when the purpose behind the rule is not jeopardized.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
538 F.3d 979, 2008 U.S. App. LEXIS 17842, 2008 WL 3876312, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hinz-v-neuroscience-inc-ca8-2008.